Biopsy Needle Top Companies-Recent Developments, Business Strategy, Deal Strategy, Patent Strategy, Benchmarking and Management Outlook

Biopsy Needle Market Size Analysis and Top Companies

The global biopsy needle market size is expected to reach around USD 2.63 billion by 2033 from USD 1.30 billion in 2023, expanding at a CAGR of 7.3% from 2024 to 2033 The top companies operating in the biopsy needle market are Becton, Medtronic Plc, Cardinal Health, Hologic Inc, Olympus Corporation, Argon Medical Devices Inc, Devicor Medical Products, Inc, B. Braun Melsungen AG, Cook Group Incorporated, Boston Scientific Corporation, FUJIFILM Holdings Corporation, Dickinson and Company, Stryker Corporation, INRAD, Inc, and Others.

Market Report Coverage

Biopsy Needle key Players

• Becton
• Medtronic Plc
• Cardinal Health
• Hologic Inc
• Olympus Corporation
• Argon Medical Devices Inc
• Devicor Medical Products, Inc
• B. Braun Melsungen AG
• Cook Group Incorporated
• Boston Scientific Corporation
• FUJIFILM Holdings Corporation
• Dickinson and Company
• Stryker Corporation
• INRAD, Inc

Recent Developments

• In 2022, Cambridge Enterprise introduced their biopsy device named ‘CamPROBE’. The prostate biopsy device aims to reduce the risks related to conventional transrectal biopsies.
• In 2022, Mammatome introduced their dual-core biopsy system which marked their first step in the core biopsy market. The device reduces the vibrations and needle movements and helps to enhance the patient experience.
• In 2022, Limaca Medical received its breakthrough device through the FDA for its Precision-GI endoscopic ultrasound biopsy needle. The invention aims to reduce issues like blood contamination, tissue fragmentation, and less collection of sample quantity during the entire procedure.
• In 2021, Hologic Inc. acquired a company named Somatex Technologies for 64 million, aiming to increase the treatment offerings for breast cancer.

We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344